British watchdog wants U.S. biotech Alexion to justify cost of drug

[Reuters – UK Focus] – Britain’s healthcare costs watchdog has asked U.S. biotech group Alexion Pharmaceuticals (NasdaqGS: ALXN – news) to explain the high price for its Soliris drug before deciding whether the treatment should be paid for by the state h more

View todays social media effects on ALXN

View the latest stocks trending across Twitter. Click to view dashboard

See who Alexion is hiring next, click here to view